{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:12:22Z","timestamp":1790341942085,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11030-024-10917-6","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T08:01:47Z","timestamp":1720598507000},"page":"5075-5084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Elucidating CTLA-4\u2019s role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments"],"prefix":"10.1007","volume":"29","author":[{"given":"Juan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"10917_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11684-022-0922-5","volume":"16","author":"Y Yu","year":"2022","unstructured":"Yu Y (2022) Multi-target combinatory strategy to overcome tumor immune escape. Frontiers of Medicine 16:208\u2013215. https:\/\/doi.org\/10.1007\/s11684-022-0922-5","journal-title":"Frontiers of Medicine"},{"key":"10917_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH (2023) Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol 23:90\u2013105. https:\/\/doi.org\/10.1038\/s41577-022-00732-1","journal-title":"Nat Rev Immunol"},{"key":"10917_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","volume":"15","author":"Y Yan","year":"2022","unstructured":"Yan Y, Huang L, Liu Y, Yi M, Chu Q, Jiao D, Wu K (2022) Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol 15:104. https:\/\/doi.org\/10.1186\/s13045-022-01322-3","journal-title":"J Hematol Oncol"},{"key":"10917_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153788","author":"R Ephraim","year":"2022","unstructured":"Ephraim R, Fraser S, Nurgali K, Apostolopoulos V (2022) Checkpoint Markers and tumor microenvironment: what do we know? Cancers. https:\/\/doi.org\/10.3390\/cancers14153788","journal-title":"Cancers"},{"key":"10917_CR5","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.cell.2015.08.038","volume":"162","author":"DR Littman","year":"2015","unstructured":"Littman DR (2015) Releasing the brakes on cancer immunotherapy. Cell 162:1186\u20131190. https:\/\/doi.org\/10.1016\/j.cell.2015.08.038","journal-title":"Cell"},{"key":"10917_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng W-J, Liu Z, Cheng Q (2021) Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res 40:184. https:\/\/doi.org\/10.1186\/s13046-021-01987-7","journal-title":"J Exp Clin Cancer Res"},{"key":"10917_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-019-0487-x","author":"V Lemiale","year":"2019","unstructured":"Lemiale V, Meert A-P, Vincent F, Darmon M, Bauer PR, Van de Louw A, Azoulay E (2019) Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Annal Intens Care. https:\/\/doi.org\/10.1186\/s13613-019-0487-x","journal-title":"Annal Intens Care"},{"key":"10917_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101174","author":"SY Gun","year":"2019","unstructured":"Gun SY, Lee SWL, Sieow JL, Wong SC (2019) Targeting immune cells for cancer therapy. Redox Biol. https:\/\/doi.org\/10.1016\/j.redox.2019.101174","journal-title":"Redox Biol"},{"key":"10917_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101298","author":"H Lingel","year":"2019","unstructured":"Lingel H, Brunner-Weinzierl MC (2019) CTLA-4 (CD152): A versatile receptor for immune-based therapy. Seminars Immunol. https:\/\/doi.org\/10.1016\/j.smim.2019.101298","journal-title":"Seminars Immunol"},{"key":"10917_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM (2018) CTLA-4: a moving target in immunotherapy. Blood, The Journal of the American Society of Hematology 131:58\u201367. https:\/\/doi.org\/10.1182\/blood-2017-06-741033","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10917_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073529","author":"G Baldanzi","year":"2022","unstructured":"Baldanzi G (2022) Immune Checkpoint Receptors Signaling in T Cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23073529","journal-title":"Int J Mol Sci"},{"key":"10917_CR12","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1182\/blood-2008-01-133736","volume":"113","author":"J Kurtz","year":"2009","unstructured":"Kurtz J, Raval F, Vallot C, Der J, Sykes M (2009) CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80\/86 to promote tolerance. Blood J Am Soc Hematol 113:3475\u20133484. https:\/\/doi.org\/10.1182\/blood-2008-01-133736","journal-title":"Blood J Am Soc Hematol"},{"key":"10917_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/82_2017_61","volume":"410","author":"S Chikuma","year":"2017","unstructured":"Chikuma S (2017) CTLA-4, an essential immune-checkpoint for T-cell activation. Curr Top Microbiol Immunol 410:99\u2013126. https:\/\/doi.org\/10.1007\/82_2017_61","journal-title":"Curr Top Microbiol Immunol"},{"key":"10917_CR14","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/cas.15756","volume":"114","author":"T Watanabe","year":"2023","unstructured":"Watanabe T, Ishino T, Ueda Y, Nagasaki J, Sadahira T, Dansako H, Araki M, Togashi Y (2023) Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. Cancer Sci 114:1859\u20131870. https:\/\/doi.org\/10.1111\/cas.15756","journal-title":"Cancer Sci"},{"key":"10917_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.trecan.2017.06.005","volume":"3","author":"H Wang","year":"2017","unstructured":"Wang H, Franco F, Ho P-C (2017) Metabolic regulation of tregs in cancer: opportunities for immunotherapy. Trends in Cancer 3:583\u2013592. https:\/\/doi.org\/10.1016\/j.trecan.2017.06.005","journal-title":"Trends in Cancer"},{"issue":"30","key":"10917_CR16","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"M Tekguc","year":"2021","unstructured":"Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S (2021) Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci 118(30):e2023739118. https:\/\/doi.org\/10.1073\/pnas.2023739118","journal-title":"Proc Natl Acad Sci"},{"key":"10917_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.Cd-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-1059","journal-title":"Cancer Discov"},{"key":"10917_CR18","doi-asserted-by":"publisher","first-page":"6027305","DOI":"10.1155\/2017\/6027305","volume":"2017","author":"R Singh","year":"2017","unstructured":"Singh R, Mishra MK, Aggarwal H (2017) Inflammation, immunity, and cancer. Hindawi 2017:6027305. https:\/\/doi.org\/10.1155\/2017\/6027305","journal-title":"Hindawi"},{"key":"10917_CR19","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1038\/s41467-018-06090-8","volume":"9","author":"H Kim","year":"2018","unstructured":"Kim H, Mun Y, Lee K, Park Y, Park J, Park J, Jeon B, Kim C, Jun Y, Hyun Y (2018) T cell microvilli constitute immunological synaptosomes that carry messages to antigen-presenting cells. Nat Commun 9:3630. https:\/\/doi.org\/10.1038\/s41467-018-06090-8","journal-title":"Nat Commun"},{"key":"10917_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LSK, Sansom DM (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600\u2013603. https:\/\/doi.org\/10.1126\/science.1202947","journal-title":"Science"},{"key":"10917_CR21","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.4049\/jimmunol.1401876","volume":"194","author":"TZ Hou","year":"2015","unstructured":"Hou TZ, Qureshi OS, Wang CJ, Baker J, Young SP, Walker LSK, Sansom DM (2015) A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T Cells. J Immunol 194:2148\u20132159. https:\/\/doi.org\/10.4049\/jimmunol.1401876","journal-title":"J Immunol"},{"key":"10917_CR22","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25:9543\u20139553. https:\/\/doi.org\/10.1128\/MCB.25.21.9543-9553.2005","journal-title":"Mol Cell Biol"},{"key":"10917_CR23","doi-asserted-by":"publisher","unstructured":"Ovcinnikovs V, Ross EM, Petersone L, Edner NM, Heuts F, Ntavli E, Kogimtzis A, Kennedy A, Wang C J and Bennett C L (2019) CTLA-4\u2013mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells. Sci Immunol 4: eaaw0902. https:\/\/doi.org\/10.1126\/sciimmunol.aaw0902","DOI":"10.1126\/sciimmunol.aaw0902"},{"key":"10917_CR24","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.Ccr-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P (2019) Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in Human Cancers. Clin Cancer Res 25:1233\u20131238. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0762","journal-title":"Clin Cancer Res"},{"key":"10917_CR25","doi-asserted-by":"publisher","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","volume":"9","author":"S Koyama","year":"2021","unstructured":"Koyama S, Nishikawa H (2021) Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer 9:e002591. https:\/\/doi.org\/10.1136\/jitc-2021-002591","journal-title":"J Immunother Cancer"},{"key":"10917_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.4049\/jimmunol.177.2.896","volume":"177","author":"AG Jarnicki","year":"2006","unstructured":"Jarnicki AG, Lysaght J, Todryk S, Mills KHG (2006) Suppression of antitumor immunity by IL-10 and TGF-\u03b2-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177:896\u2013904. https:\/\/doi.org\/10.4049\/jimmunol.177.2.896","journal-title":"J Immunol"},{"key":"10917_CR27","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1111\/ajt.12938","volume":"14","author":"SM Krummey","year":"2014","unstructured":"Krummey SM, Ford ML (2014) Braking bad: novel mechanisms of CTLA-4 inhibition of T cell responses. Am J Transplant 14:2685\u20132690. https:\/\/doi.org\/10.1111\/ajt.12938","journal-title":"Am J Transplant"},{"key":"10917_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","volume":"45","author":"LS Walker","year":"2013","unstructured":"Walker LS (2013) Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun 45:49\u201357. https:\/\/doi.org\/10.1016\/j.jaut.2013.06.006","journal-title":"J Autoimmun"},{"key":"10917_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imr.12721","volume":"287","author":"N Mitsuiki","year":"2019","unstructured":"Mitsuiki N, Schwab C, Grimbacher B (2019) What did we learn from CTLA-4 insufficiency on the human immune system? Immunol Rev 287:33\u201349. https:\/\/doi.org\/10.1111\/imr.12721","journal-title":"Immunol Rev"},{"key":"10917_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro B, Gomez-Martin C, de la Mata M, I\u00f1arrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59:81\u201388. https:\/\/doi.org\/10.1016\/j.jhep.2013.02.022","journal-title":"J Hepatol"},{"key":"10917_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet 397:375\u2013386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8","journal-title":"The Lancet"},{"key":"10917_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/onco.13819","volume":"26","author":"MT Saung","year":"2021","unstructured":"Saung MT, Pelosof L, Casak S, Donoghue M, Lemery S, Yuan M, Rodriguez L, Schotland P, Chuk M, Davis G (2021) FDA approval summary: nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib. Oncologist 26:797\u2013806. https:\/\/doi.org\/10.1002\/onco.13819","journal-title":"Oncologist"},{"key":"10917_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4101","author":"L Bai","year":"2021","unstructured":"Bai L, Sun M, Xu A, Bai Y, Wu J, Shao G, Song L, Jin X, Song W, Li B (2021) Phase 2 study of AK104 (PD-1\/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma. Wolters Kluwer Health. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4101","journal-title":"Wolters Kluwer Health"},{"key":"10917_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.379","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang Y-K, Dao TV, De Toni EN (2022) Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Proc Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.379","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10917_CR35","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Cadonilimab: first approval. Drugs 82:1333\u20131339. https:\/\/doi.org\/10.1007\/s40265-022-01761-9","journal-title":"Drugs"},{"key":"10917_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.106","author":"J Wang","year":"2022","unstructured":"Wang J, Lou H, Cai H-B, Huang X, Li G, Wang L, Liu T, Liu W, Li B, Xia Y (2022) A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R\/M CC). Proc Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.106","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10917_CR37","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/S0090-8258(22)01293-8","volume":"166","author":"X Wu","year":"2022","unstructured":"Wu X, Ji J, Lou H, Li Y, Feng M, Xu N, Li Y, Wang J, Huang Y, Lou G (2022) Efficacy and safety of cadonilimab, an anti-PD-1\/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R\/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075). Gynecol Oncol 166:S47\u2013S48. https:\/\/doi.org\/10.1016\/S0090-8258(22)01293-8","journal-title":"Gynecol Oncol"},{"key":"10917_CR38","doi-asserted-by":"publisher","unstructured":"Zhang L, Zhao H, Ma Y, Huang Y, Zhang Y, Wei X, Yang Y, Yang W, Liu F and Lin Z (2021). Development and preliminary clinical activity of QL1706 (PSB205), a combination of anti-PD1 and anti-CTLA-4 antibodies manufactured together as a single product. In Cancer research, Amer assoc cancer research 615 chestnut st, 17th floor, philadelphia, PA. https:\/\/doi.org\/10.1158\/1538-7445.AM2021-CT119","DOI":"10.1158\/1538-7445.AM2021-CT119"},{"key":"10917_CR39","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/s0140-6736(22)01659-2","volume":"400","author":"S Kim","year":"2022","unstructured":"Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen D-T, Berglund A, Michael L, Aoki M, Wang M-H, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS (2022) Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. The Lancet 400:1008\u20131019. https:\/\/doi.org\/10.1016\/s0140-6736(22)01659-2","journal-title":"The Lancet"},{"key":"10917_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu T-E, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211. https:\/\/doi.org\/10.1016\/S1470-2045(20)30641-0","journal-title":"Lancet Oncol"},{"key":"10917_CR41","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim S-W, Ursol G, Hussein M, Lim FL (2023) Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol 41:1213. https:\/\/doi.org\/10.1200\/JCO.22.00975","journal-title":"J Clin Oncol"},{"key":"10917_CR42","doi-asserted-by":"publisher","first-page":"S1423","DOI":"10.1016\/j.annonc.2022.08.058","volume":"33","author":"M Ahn","year":"2022","unstructured":"Ahn M, Kim S, Costa EC, Rodr\u00edguez L, Oliveira J, Molla MI, Majem M, Costa L, Su W, Lee K (2022) LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin\/pemetrexed (CP) in treatment-na\u00efve (1L) non-small cell lung cancer (NSCLC): A phase Ib\/II trial. Ann Oncol 33:S1423. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.058","journal-title":"Ann Oncol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10917-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10917-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10917-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:03:09Z","timestamp":1758600189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10917-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10917"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10917-6","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}